dm+d

16602005

Articles

Hydrocortisone products: information for supporting intrathecal risk assessment

11 August 2022Hydrocortisone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Hydrocortisone acetate products: information for supporting intrathecal risk assessment

11 August 2022Hydrocortisone acetate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Search Articles

Refrigerated Storage

TimodineAlliance Pharmaceuticals

Alliance Pharmaceuticals
Timodine
Cream (contains nystatin, dimeticone, hydrocortisone and benzalkonium chloride)

Contact Alliance Pharmaceuticals in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

19 March 2021
London MI Service

HydrocortisoneColonis Pharma

Colonis Pharma
Hydrocortisone
Oral solution (5mg/5mL, 10mg/5mL)

Contact Colonis Pharma in all cases where a deviation from the recommended storage conditions has occurred.

Refer to the electronic medicines compendium (eMC) at https://www.medicines.org.uk for company contact details.

13 October 2022
London MI Service

Medicine Compliance Aid Stability

genericAccord-UK Ltd

Accord-UK Ltd
generic
Tablets 10mg, 20mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Store in airtight containers.
20 December 2022

PlenadrenViroPharma Ltd

ViroPharma Ltd
Plenadren
Tablets m/r 5mg, 20mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Store in airtight containers.
22 November 2022

Non-proprietaryAccord-UK Ltd

Accord-UK Ltd
Non-proprietary
Tablets mucoadhesive buccal 2.5mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Mucoadhesive buccal tablets.
20 December 2022

Lactation Safety Information

Oral / parenteral

Oral / parenteral
Yes
No published evidence of safety
Normal component of breast-milk
Used in full-term neonates from birth
Doses up to 160mg daily unlikely to cause adverse effects in the infant
9 November 2020

Local injection

Local injection
Yes
11 September 2020

In the ear

In the ear
Yes
Only available in combination with gentamicin for which there are no additional risks
11 September 2020

Orophayngeal - buccal tablets

Orophayngeal -
buccal tablets
Yes
11 September 2020

Topical

Topical
Yes
Low potency
There are no additional risks when used in combination topical preparations containing antimicrobials or urea
11 September 2020

Rectal for inflammatory bowel disease

Rectal
for inflammatory bowel disease
Yes
-
No published evidence of safety after rectal administration
Small amounts in breast milk after oral administration
Doses up to 50mg orally daily unlikely to cause adverse effects in the infant
11 September 2020